Ultragenyx Pharmaceutical
Novato · Founded 2010
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical develops therapeutics for rare diseases, sometimes referred to as Orphan products. Ultragenyx is a efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team's experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $500K – $1M
- Total funding: $1.5B
- Funding stage: IPO
- Last round: Post-IPO Debt (Nov 2025)
- Ticker: nasdaq:RARE
- Website: ultragenyx.com
- Phone: +1 415 483 8800
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ultragenyx-pharmaceutical-33103 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.